IMVT catalyst calendar

Immunovant, Inc.

Upcoming catalysts
9
Cash runway
19.2 months
Cash & investments
$798M
Phase 3 programs
5

Immunovant, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Biological Products, (No Diagnostic Substances).

The next scheduled catalyst is A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE) on October 15, 2026. There are 9 upcoming events on record.

Cash runway is approximately 19.2 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.

Across 11 concluded trials, 45% reached completion rather than being terminated or withdrawn.

Upcoming catalysts

DateEventTypePhase
October 15, 2026 A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE) Trial Milestone Phase 2
November 2, 2026 est. Next quarterly earnings (projected) Earnings —
May 15, 2027 A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease Trial Milestone Phase 2
September 15, 2027 A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis Trial Milestone Phase 2
December 15, 2027 Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis Trial Milestone Phase 3
June 15, 2028 A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease Trial Milestone Phase 2
July 15, 2028 Efficacy and Safety of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease Activity Trial Milestone Phase 2
August 15, 2028 Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Trial Milestone Phase 2
March 15, 2030 A Long-Term Extension Study of IMVT-1402 in Adult Participants With Graves' Disease (GD) Trial Milestone Phase 2

Track IMVT alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open IMVT in the tracker

Recent history

DateEventTypePhase
August 6, 2026 Quarterly results filed (8-K) Earnings —
July 20, 2026 To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP Trial Milestone Phase 2
July 16, 2026 An Open-Label Extension Study of Batoclimab in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Trial Milestone Phase 2
May 20, 2026 Quarterly results filed (8-K) Earnings —
April 2, 2026 Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease Trial Milestone Phase 3
February 6, 2026 Quarterly results filed (8-K) Earnings —
February 3, 2026 Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease Trial Milestone Phase 3
December 12, 2025 8-K filed: Other event Filing —
December 11, 2025 8-K filed: Other event Filing —
November 21, 2025 8-K filed: Leadership change Corporate —
November 10, 2025 Quarterly results filed (8-K) Earnings —
November 2, 2025 Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease Trial Milestone Phase 3
September 3, 2025 8-K filed: Reg FD disclosure, Other event Filing —
August 11, 2025 Quarterly results filed (8-K) Earnings —
July 29, 2025 8-K filed: Leadership change Corporate —
July 25, 2025 A Proof-of-Concept Study to Assess Batoclimab in Participants With Graves' Disease Trial Milestone Phase 2
May 29, 2025 Quarterly results filed (8-K) Earnings —
April 21, 2025 8-K filed: Leadership change, Reg FD disclosure, Other event Corporate —
January 10, 2025 Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis Trial Milestone Phase 3
April 1, 2021 To Assess the Efficacy and Safety of RVT-1401 in the Treatment of Warm Autoimmune Hemolytic Anemia (ASCEND-WAIHA). Trial Milestone Phase 2
February 2, 2021 ASCEND GO-2: Study of RVT-1401 for the Treatment of Participants With Active, Moderate to Severe Graves' Ophthalmopathy ( GO ) Trial Milestone Phase 2
October 7, 2020 A Study of RVT-1401 in Myasthenia Gravis (MG) Patients Trial Milestone Phase 2
February 29, 2020 Study of RVT-1401 for the Treatment of Patients With Moderate to Severe Active Graves' Ophthalmopathy (GO) Trial Milestone Phase 2

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.